Memorial Sloan-Kettering Cancer Center Researchers Update Knowledge of Prostate Cancer (Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer)

Press/Media

Period15 Dec 2023

Media coverage

1

Media coverage

  • TitleMemorial Sloan-Kettering Cancer Center Researchers Update Knowledge of Prostate Cancer (Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer)
    Media name/outletImmunotherapy Daily
    Country/TerritoryUnited States
    Date15/12/23
    PersonsMichael Anderson
View all 1
View less